country

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-109184

Copy Link Print Information

Murizatoclax

(Synonyms: AMG 397)

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

Murizatoclax (AMG 397) is a potent, selective and orally active inhibitor of myeloid leukemia 1 (MCL-1) inhibitor, with a K_i of 15 pM. Murizatoclax competitive binds to the BH3-binding groove of MCL1 with pro-apoptotic BCL-2 family members. Murizatoclax can be used for the research of cancer.

For research use only. We do not sell to patients.

Purity: 98.47%
CAS No.: 2245848-05-7
Formula: C₄₂H₅₇ClN₄O₅S
Molecular Weight:765.44

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Murizatoclax Chemical Structure

CAS No.: 2245848-05-7

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

MCL1

15 pM (Ki)

All Bcl-2 Family Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
AMO1	EC₅₀	13.5 nM Compound: AMG 397	Antiproliferative activity against human AMO1 cells assessed as reduction in cell viability Antiproliferative activity against human AMO1 cells assessed as reduction in cell viability	[PMID: 38597264]
MV4-11	EC₅₀	43.6 nM Compound: AMG 397	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability	[PMID: 38597264]
NCI-H929	EC₅₀	13 nM Compound: AMG 397	Antiproliferative activity against human NCI-H929 cells assessed as reduction in cell viability Antiproliferative activity against human NCI-H929 cells assessed as reduction in cell viability	[PMID: 38597264]
OPM-2	IC₅₀	70 nM Compound: AMG397	Anticancer activity against human OPM-2 cells assessed as inhibition of cell viability incubated for 24 hrs in presence of 10% FBS by Cell-titer Glo assay Anticancer activity against human OPM-2 cells assessed as inhibition of cell viability incubated for 24 hrs in presence of 10% FBS by Cell-titer Glo assay	[PMID: 33253879]

In Vitro

AMG 397 potently disrupts the interaction between MCL1 and BIM in OPM2 cells, induces clear increases in Caspase-3/7 activity within one hour^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Murizatoclax (25-50 mg/kg; p.o. once or twice weekly) exhibits significant tumor regressions in mice bearing OPM2 xenografts^[2].
Murizatoclax (10-60 mg/kg; p.o. twice weekly) achieves 47% MOLM-13 orthotopic tumor growth inhibition (TGI), 99% TGI and 75% regression at the dose of 10, 30 and 60 mg/kg, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 2245848-05-7
Appearance Solid
Molecular Weight 765.44
Formula C₄₂H₅₇ClN₄O₅S
Color White to off-white
SMILES

O=C(C(C=C1)=CC2=C1OC[C@]3(CCCC4=C3C=CC(Cl)=C4)CN2C[C@@]5([H])[C@](CC5)([H])[C@](CN6C[C@](CCCC7)([H])N7CC6)(OC)/C=C/C[C@H](C)[C@H]8C)NS8(=O)=O
Synonyms

AMG 397
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

bioRxiv

A framework for target discovery in rare cancers. [Abstract]

2024 Nov 20:2024.10.24.620074. PMID: 39484513

Solvent & Solubility

In Vitro:

DMSO : 10 mg/mL (13.06 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.3064 mL

6.5322 mL

13.0644 mL

5 mM

0.2613 mL

1.3064 mL

2.6129 mL

10 mM

0.1306 mL

0.6532 mL

1.3064 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Wang H, et, al. Targeting MCL-1 in cancer: current status and perspectives. J Hematol Oncol. 2021 Apr 21;14(1):67. [Content Brief]

[2]. Caenepeel S, et al. Abstract 6218: discovery and preclinical evaluation of AMG 397, a potent, selective and orally bioavailable MCL1 inhibitor. Cancer Res. 2020;80(16 Supplement):6218.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.3064 mL	6.5322 mL	13.0644 mL	32.6610 mL
	5 mM	0.2613 mL	1.3064 mL	2.6129 mL	6.5322 mL
	10 mM	0.1306 mL	0.6532 mL	1.3064 mL	3.2661 mL

Keywords

100 mg

Get Quote In-stock

Amount: USD 0.00

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
- In Vivo Dissolution Calculator
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Murizatoclax

Publications Citing Use of MedChemExpress (MCE) Murizatoclax

All Bcl-2 Family Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Murizatoclax Related Classifications

Cat. No.: HY-109184